Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
62
Recruiting, industry sponsors, Ophthalmology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed555
62 trials
Showing 1 to 25, recently updated first.
Sumitomo Pharma America, Inc.Industry
NCT06891885 · 12 participants (planned) · Start Apr 16, 2026 · Primary completion Oct 31, 2028
Drug: DSP-3077 Retinal Sheet Cohort 1; DSP-3077 Retinal Sheet Cohort 2 and 1 more · For: Retinitis Pigmentosa
Sites: Boston, Massachusetts; Minneapolis, Minnesota
- A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationPivotal-lookingRecruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07851259 · 321 participants (planned) · Start Jan 8, 2027 · Primary completion Aug 21, 2030
Drug: RO7965032; Placebo · For: Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sites: Walnut Creek, California; Biloxi, Mississippi; Winston-Salem, North Carolina · 9 sites in all
BlueRock TherapeuticsIndustry
NCT06789445 · 54 participants (planned) · Start Mar 10, 2025 · Primary completion Oct 2029
Drug: OpCT-001; OpCT-001 · For: Primary Photoreceptor Disease; Retinitis Pigmentosa (RP); Usher Syndrome and 6 more
Sites: Los Angeles, California; Miami, Florida; Philadelphia, Pennsylvania · 5 sites in all
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)Pivotal-lookingRecruiting
EyeBiotech Ltd.Industry
NCT07496567 · 960 participants (planned) · Start Apr 15, 2026 · Primary completion Jul 31, 2028
Drug: Tiespectus; Aflibercept · For: Macular Degeneration; Age-Related Macular Degeneration; Choroidal Neovascularization and 1 more
Sites: Gilbert, Arizona; Phoenix, Arizona; Encino, California · 121 sites in all
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)Pivotal-lookingRecruiting
EyeBiotech Ltd.Industry
NCT07440225 · 960 participants (planned) · Start Mar 27, 2026 · Primary completion Jun 30, 2028
Drug: Tiespectus; Aflibercept · For: Macular Degeneration; Age-Related Macular Degeneration; Choroidal Neovascularization and 1 more
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Springdale, Arkansas · 148 sites in all
- A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)Recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07861074 · 87 participants (planned) · Start Nov 4, 2026 · Primary completion Jun 5, 2029
Drug: Tulisokibart; Placebo and 1 more · For: Noninfectious Intermediate, Posterior, or Panuveitis
Sites: Plano, Texas; Vancouver, Canada
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05626114 · 60 participants (planned) · Start Mar 23, 2023 · Primary completion Mar 1, 2031
Drug: OpRegen · For: Geographic Atrophy
Sites: Beverly Hills, California; Sacramento, California; San Francisco, California · 17 sites in all
- Phase 2 Study of ADX-038 in Participants With Geographic AtrophyPivotal-lookingRecruiting
ADARx Pharmaceuticals, Inc.Industry
NCT06990269 · 240 participants (planned) · Start Nov 10, 2025 · Primary completion Feb 28, 2030
Drug: ADX-038; Placebo · For: Geographic Atrophy Secondary to Age-related Macular Degeneration
Sites: Gilbert, Arizona; Phoenix, Arizona; Bakersfield, California · 83 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT07553429 · 49 participants (planned) · Start May 14, 2026 · Primary completion Mar 23, 2027
Drug: Low dose BI 3812465; Medium dose BI 3812465 and 1 more · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Scottsdale, Arizona; Arcadia, California · 29 sites in all
- A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve DamagePivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07770685 · 156 participants (planned) · Start Oct 7, 2026 · Primary completion Jul 31, 2030
Drug: ASP2767; Sham ASP2767 and 3 more · For: Glaucoma
Sites: Boston, Massachusetts
- A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular EdemaPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06962839 · 300 participants (planned) · Start Jun 5, 2025 · Primary completion Mar 1, 2028
Drug: BI 1815368; Placebo · For: Macular Edema
Sites: Phoenix, Arizona; Arcadia, California; Huntington Beach, California · 98 sites in all
- A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMDPivotal-lookingRecruiting
Galimedix Therapeutics IncIndustry
NCT06659549 · 110 participants (planned) · Start Jan 10, 2025 · Primary completion Mar 30, 2028
Drug: GAL-101; Placebo · For: Geographic Atrophy of the Macula
Sites: Beverly Hills, California; Walnut Creek, California; Hagerstown, Maryland · 24 sites in all
Bausch & Lomb IncorporatedIndustry
NCT07778888 · 20 participants (planned) · Start Oct 19, 2026 · Primary completion Feb 2027
Drug: BL1107 · For: Dry Eye Disease
Sites: Newport Beach, California
- A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07441642 · 272 participants (planned) · Start Mar 9, 2026 · Primary completion Aug 21, 2029
Drug: FWY003; Placebo · For: Geographic Atrophy Secondary to Age-related Macular Degeneration
Sites: Huntington Beach, California; Sacramento, California; Santa Barbara, California · 65 sites in all
- A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's DiseasePivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07737743 · 344 participants (planned) · Start Aug 24, 2026 · Primary completion Feb 19, 2029
Drug: DDY391; Placebo · For: Sjögren's Disease
Sites: Avondale, Arizona; Clearwater, Florida; Tampa, Florida · 31 sites in all
AiViva BioPharma, Inc.Industry
NCT07557121 · 35 participants (planned) · Start Jul 1, 2026 · Primary completion Jun 30, 2027
Drug: AIV007; EYLEA® (aflibercept) Injection 2 mg (0.05mL) · For: Neovascular (Wet) Age-Related Macular Degeneration
Sites: Torrance, California; McAllen, Texas
Tavo BiotherapeuticsIndustry
NCT07913074 · 96 participants (planned) · Start Oct 23, 2026 · Primary completion Jun 30, 2027
Drug: Arm 1: TB0001 ophthalmic solution 0.9%; Arm 2: TB0001 ophthalmic solution 1.2% and 2 more · For: Primary Open - Angle Glaucoma (POAG); Ocular Hypertension (OHT)
Sites: Glendale, California; Newport Beach, California; Lynchburg, Virginia
- A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)Pivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06635148 · 274 participants (planned) · Start Sep 19, 2024 · Primary completion Aug 24, 2029
Drug: JNJ-81201887 · For: Geographic Atrophy; Macular Degeneration
Sites: Tucson, Arizona; Fullerton, California; La Jolla, California · 104 sites in all
- Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular EdemaPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07592273 · 576 participants (planned) · Start Jun 1, 2026 · Primary completion Jun 2028
Drug: Surabgene Lomparvovec; Sham and 2 more · For: Diabetic Retinopathy
Sites: Mesa, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 40 sites in all
Fujian Haixi Pharmaceuticals Co., Ltd.Industry
NCT07185841 · 198 participants (planned) · Start Jul 1, 2025 · Primary completion Jul 1, 2028
Drug: HX9428 tablet · For: Wet Age-related Macular Degeneration (AMD)
Sites: Beijing, China
Lubris Bio Pty LtdIndustry
NCT07118241 · 80 participants (planned) · Start Sep 17, 2025 · Primary completion Dec 30, 2026
Drug: Recombinant Human Proteoglycan 4; Vehicle Control · For: Sjögren's Syndrome
Sites: Sydney, Australia; Brisbane, Australia; Maroochydore, Australia · 7 sites in all
- Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)Pivotal-lookingRecruiting
Ray Therapeutics, Inc.Industry
NCT07901751 · 60 participants (planned) · Start Oct 2026 · Primary completion Oct 2028
Drug: RTx-015 · For: Retinitis Pigmentosa (RP); Inherited Retinal Diseases
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 14 sites in all
- A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular EdemaPivotal-lookingRecruiting
BioAge Labs, Inc.Industry
NCT07812090 · 180 participants (planned) · Start Aug 21, 2026 · Primary completion Nov 2027
Drug: Oral BGE-102; Oral Placebo Matching BGE-102 and 1 more · For: Diabetic Macular Edema (DME)
Sites: Bakersfield, California; Glendale, California; Mountain View, California · 16 sites in all
Lubris Bio Pty LtdIndustry
NCT07118254 · 15 participants (planned) · Start Sep 17, 2025 · Primary completion Mar 2027
Drug: rhPRG4 450ug/ml; Vehicle Control · For: Ocular Graft Versus Host Disease
Sites: Sydney, Australia; Brisbane, Australia; Melbourne, Australia
- An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye DiseasePivotal-lookingRecruiting
Dompé Farmaceutici S.p.AIndustry
NCT07503886 · 417 participants (planned) · Start May 12, 2026 · Primary completion Dec 27, 2026
Drug: DFL24498 · For: Dry Eye Disease (DED)
Sites: Chandler, Arizona; Azusa, California; Glendale, California · 24 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.